» Articles » PMID: 36793052

Sarcomatoid Renal Cell Carcinoma: MRI Features and Their Association with Survival

Overview
Journal Cancer Imaging
Publisher Springer Nature
Specialties Oncology
Radiology
Date 2023 Feb 16
PMID 36793052
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To evaluate MRI features of sarcomatoid renal cell carcinoma (RCC) and their association with survival.

Methods: This retrospective single-center study included 59 patients with sarcomatoid RCC who underwent MRI before nephrectomy during July 2003-December 2019. Three radiologists reviewed MRI findings of tumor size, non-enhancing areas, lymphadenopathy, and volume (and percentage) of T2 low signal intensity areas (T2LIA). Clinicopathological factors of age, gender, ethnicity, baseline metastatic status, pathological details (subtype and extent of sarcomatoid differentiation), treatment type, and follow-up were extracted. Survival was estimated using Kaplan-Meier method and Cox proportional-hazards regression model was used to identify factors associated with survival.

Results: Forty-one males and eighteen females (median age 62 years; interquartile range 51-68) were included. T2LIAs were present in 43 (72.9%) patients. At univariate analysis, clinicopathological factors associated with shorter survival were: greater tumor size (> 10 cm; HR [hazard ratio] = 2.44, 95% CI 1.15-5.21; p = 0.02), metastatic lymph nodes (present; HR = 2.10, 95% CI 1.01-4.37; p = 0.04), extent of sarcomatoid differentiation (non-focal; HR = 3.30, 95% CI 1.55-7.01; p < 0.01), subtypes other than clear cell, papillary, or chromophobe (HR = 3.25, 95% CI 1.28-8.20; p = 0.01), and metastasis at baseline (HR = 5.04, 95% CI 2.40-10.59; p < 0.01). MRI features associated with shorter survival were: lymphadenopathy (HR = 2.24, 95% CI 1.16-4.71; p = 0.01) and volume of T2LIA (> 3.2 mL, HR = 4.22, 95% CI 1.92-9.29); p < 0.01). At multivariate analysis, metastatic disease (HR = 6.89, 95% CI 2.79-16.97; p < 0.01), other subtypes (HR = 9.50, 95% CI 2.81-32.13; p < 0.01), and greater volume of T2LIA (HR = 2.51, 95% CI 1.04-6.05; p = 0.04) remained independently associated with worse survival.

Conclusion: T2LIAs were present in approximately two thirds of sarcomatoid RCCs. Volume of T2LIA along with clinicopathological factors were associated with survival.

Citing Articles

Development and validation of intravoxel incoherent motion diffusion weighted imaging-based model for preoperative distinguishing nuclear grade and survival of clear cell renal cell carcinoma complicated with venous tumor thrombus.

Zhao J, Xu H, Fu Y, Ding X, Wang M, Peng C Cancer Imaging. 2024; 24(1):164.

PMID: 39695867 PMC: 11654007. DOI: 10.1186/s40644-024-00816-2.


Imaging in Renal Cell Carcinoma Detection.

Woon D, Qin S, Al-Khanaty A, Perera M, Lawrentschuk N Diagnostics (Basel). 2024; 14(18).

PMID: 39335784 PMC: 11431198. DOI: 10.3390/diagnostics14182105.


CT and MRI features of sarcomatoid urothelial carcinoma of the bladder and its differential diagnosis with conventional urothelial carcinoma.

Zhuo J, Han J, Yang L, Wang Y, Shi G, Yan Z Cancer Imaging. 2024; 24(1):102.

PMID: 39095926 PMC: 11295343. DOI: 10.1186/s40644-024-00748-x.


Renal cell carcinoma and venous tumor thrombus: predicting sarcomatoid dedifferentiation through preoperative IVIM-based MR imaging.

Zhao J, Ding X, Zhou S, Wang M, Peng C, Bai X Abdom Radiol (NY). 2024; 49(6):1961-1974.

PMID: 38411691 DOI: 10.1007/s00261-024-04210-1.

References
1.
Nguyen D, Vertosick E, Corradi R, Vilaseca A, Benfante N, Touijer K . Histological subtype of renal cell carcinoma significantly affects survival in the era of partial nephrectomy. Urol Oncol. 2016; 34(6):259.e1-8. PMC: 5133368. DOI: 10.1016/j.urolonc.2016.01.005. View

2.
Blum K, Gupta S, Tickoo S, Chan T, Russo P, Motzer R . Sarcomatoid renal cell carcinoma: biology, natural history and management. Nat Rev Urol. 2020; 17(12):659-678. PMC: 7551522. DOI: 10.1038/s41585-020-00382-9. View

3.
Siegel R, Miller K, Fuchs H, Jemal A . Cancer statistics, 2022. CA Cancer J Clin. 2022; 72(1):7-33. DOI: 10.3322/caac.21708. View

4.
Bi M, Zhao S, Said J, Merino M, Adeniran A, Xie Z . Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma. Proc Natl Acad Sci U S A. 2016; 113(8):2170-5. PMC: 4776463. DOI: 10.1073/pnas.1525735113. View

5.
El Mouallem N, Smith S, Paul A . Sarcomatoid renal cell carcinoma: Biology and treatment advances. Urol Oncol. 2018; 36(6):265-271. DOI: 10.1016/j.urolonc.2017.12.012. View